Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 20/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19360806 | 0.88 | FOLH1 (0.70) | FOLH1 | |
| SCHEMBL29679449 | 0.85 | FOLH1 (0.72) | FOLH1 | |
| SCHEMBL23252351 | 0.84 | FOLH1 (0.69) | FOLH1 | |
| SCHEMBL22984225 | 0.84 | FOLH1 (0.69) | FOLH1 | |
| SCHEMBL17705986 | 0.84 | FOLH1 (0.76) | FOLH1 | |
| SCHEMBL24123178 | 0.83 | FOLH1 (0.73) | FOLH1 | |
| SCHEMBL19743110 | 0.83 | FOLH1 (0.72) | FOLH1 | |
| SCHEMBL19743111 | 0.83 | FOLH1 (0.72) | FOLH1 | |
| SCHEMBL21249161 | 0.82 | FOLH1 (0.74) | FOLH1 | |
| SCHEMBL29340071 | 0.82 | FOLH1 (0.74) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10688200-B2 | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy | FIVE ELEVEN PHARMA INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20170189568-A1 | UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THERAPY | FIVE ELEVEN PHARMA INC. | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189568-A1 | UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THERAPY | KLK3, FOLH1, UTS2R | FOLH1 2/4885 |
| US-10688200-B2 | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy | KLK3, FOLH1, UTS2R | FOLH1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.